

Human IgG-F(ab')₂ Fragment cross-adsorbed Antibody

F(ab')₂ Goat Polyclonal

Antigen Affinity Purified

Catalog No. A80-249A

Lot No. A80-249A-2



APPLICATIONS	WB, IHC, ICC, ELISA
SPECIES REACTIVITY	Human. Minimum reactivity to mouse and rat
AMOUNT	1 ml
CONCENTRATION	0.5 mg/ml
STORAGE/SHELF LIFE	2 – 8° C / 1 year from date of receipt
PHYSICAL STATE	Liquid
BUFFER	Phosphate Buffered Saline (PBS) containing 0.09% Sodium Azide
ISOTYPE	IgG
ORIGIN	USA
PRODUCTION PROCEDURES	Antiserum was solid phase adsorbed to ensure specificity. Antiserum was cross adsorbed using mouse and rat immunosorbents to remove cross reactive antibodies. The antibody to human IgG-F(ab') ₂ was isolated by affinity chromatography using antigen coupled to agarose beads. F(ab') ₂ fragments were generated using a pepsin digestion. Fc fragments and whole IgG molecules have been removed.

Antibody concentration was determined by extinction coefficient: absorbance at 280 nm of 1.4 equals 1.0 mg of IgG.

By immunoelectrophoresis and ELISA this antibody reacts specifically with F(ab')₂ fragments of human IgG. No antibody was detected against non-immunoglobulin serum proteins. Less than 1% cross reactivity to mouse and rat IgG was detected. This antibody may cross react with F(ab')₂ fragments of IgG from other species.

APPLICATIONS Centrifuge tube to remove product from lid. Optimal working dilutions should be determined experimentally by the investigator. Prepare working dilution immediately before use.

Western Blot	1:1,000 – 1:20,000
Immunohistochemistry	1:200 – 1:2,000
Immunocytochemistry	1:200 – 1:2,000
ELISA	1:1,000 – 1:20,000; for coating plates 1:50 – 1:250

APPLICATION NOTES Not all listed applications have been specifically tested by our laboratory.

ADDITIONAL INFO <https://www.bethyl.com/product/A80-249A>
Use the link above to view SDS, a current list of citations, and other product specific information.

This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc.
Brian McWilliams, PhD Date: June 22, 2021